Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty
- PMID: 22806692
- DOI: 10.1002/bit.24608
Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty
Abstract
This article evaluates the current and future potential of batch and continuous cell culture technologies via a case study based on the commercial manufacture of monoclonal antibodies. The case study compares fed-batch culture to two perfusion technologies: spin-filter perfusion and an emerging perfusion technology utilizing alternating tangential flow (ATF) perfusion. The operational, economic, and environmental feasibility of whole bioprocesses based on these systems was evaluated using a prototype dynamic decision-support tool built at UCL encompassing process economics, discrete-event simulation and uncertainty analysis, and combined with a multi-attribute decision-making technique so as to enable a holistic assessment. The strategies were compared across a range of scales and titres so as to visualize how their ranking changes in different industry scenarios. The deterministic analysis indicated that the ATF perfusion strategy has the potential to offer cost of goods savings of 20% when compared to conventional fed-batch manufacturing processes when a fivefold increase in maximum viable cell densities was assumed. Savings were also seen when the ATF cell density dropped to a threefold increase over the fed-batch strategy for most combinations of titres and production scales. In contrast, the fed-batch strategy performed better in terms of environmental sustainability with a lower water and consumable usage profile. The impact of uncertainty and failure rates on the feasibility of the strategies was explored using Monte Carlo simulation. The risk analysis results demonstrated the enhanced robustness of the fed-batch process but also highlighted that the ATF process was still the most cost-effective option even under uncertainty. The multi-attribute decision-making analysis provided insight into the limited use of spin-filter perfusion strategies in industry. The resulting sensitivity spider plots enabled identification of the critical ratio of weightings of economic and operational benefits that affect the choice between ATF perfusion and fed-batch strategies.
Copyright © 2012 Wiley Periodicals, Inc.
Similar articles
-
Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture.Biotechnol Prog. 2017 Jul;33(4):854-866. doi: 10.1002/btpr.2492. Epub 2017 Jun 2. Biotechnol Prog. 2017. PMID: 28480535 Free PMC article.
-
A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty.Biotechnol Bioeng. 2006 Mar 5;93(4):687-97. doi: 10.1002/bit.20757. Biotechnol Bioeng. 2006. PMID: 16259001
-
Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes.Biotechnol Prog. 2011 Nov-Dec;27(6):1588-98. doi: 10.1002/btpr.676. Epub 2011 Sep 23. Biotechnol Prog. 2011. PMID: 21954092
-
Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.Appl Microbiol Biotechnol. 2016 Mar;100(5):2121-32. doi: 10.1007/s00253-015-7267-9. Epub 2016 Jan 13. Appl Microbiol Biotechnol. 2016. PMID: 26758296 Free PMC article. Review.
-
In pursuit of the optimal fed-batch process for monoclonal antibody production.Biotechnol Prog. 1995 Jan-Feb;11(1):1-13. doi: 10.1021/bp00031a001. Biotechnol Prog. 1995. PMID: 7765983 Review.
Cited by
-
Production of retroviral vectors in continuous high cell density culture.Appl Microbiol Biotechnol. 2023 Oct;107(19):5947-5961. doi: 10.1007/s00253-023-12689-9. Epub 2023 Aug 5. Appl Microbiol Biotechnol. 2023. PMID: 37542575 Free PMC article.
-
A Wake-Up Call for the Efficient Use of the Bacterial Resting Cell Process, with Focus on Low Solubility Products.Curr Microbiol. 2020 Aug;77(8):1349-1362. doi: 10.1007/s00284-020-01959-8. Epub 2020 Apr 8. Curr Microbiol. 2020. PMID: 32270205 Review.
-
Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture.Biotechnol Prog. 2017 Jul;33(4):854-866. doi: 10.1002/btpr.2492. Epub 2017 Jun 2. Biotechnol Prog. 2017. PMID: 28480535 Free PMC article.
-
Continuous Manufacturing of Recombinant Drugs: Comprehensive Analysis of Cost Reduction Strategies, Regulatory Pathways, and Global Implementation.Pharmaceuticals (Basel). 2025 Aug 4;18(8):1157. doi: 10.3390/ph18081157. Pharmaceuticals (Basel). 2025. PMID: 40872548 Free PMC article. Review.
-
Triple Space-Time Yield in Discontinuous Antibody Biomanufacturing by Combination of Synergetic Process Intensification Strategies.Bioengineering (Basel). 2023 Dec 5;10(12):1391. doi: 10.3390/bioengineering10121391. Bioengineering (Basel). 2023. PMID: 38135982 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources